Basma Abdi
Paris, 75013, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 40 publications
Clearance of NNRTI resistance-associated mutations in the HIV-1 DNA reservoir with or without the presence of M184V mutation.
Journal: The Journal of antimicrobial chemotherapy
Published: January 26, 2026
Despite increasing use of integrase inhibitors to treat HIV infection, resistance to this class remains stable.
Journal: The Journal of antimicrobial chemotherapy
Published: July 29, 2025
Major role of dolutegravir in the emergence of the S147G integrase resistance mutation.
Journal: The Journal of antimicrobial chemotherapy
Published: October 14, 2024
No virological failure in patients living with HIV with past NNRTI resistance-associated mutations switched to doravirine-containing regimens.
Journal: The Journal of antimicrobial chemotherapy
Published: September 26, 2024
Changes in NNRTI use have not altered the ecology of NNRTI resistance over the last 10 years in people with HIV experiencing virological failure on antiretroviral drugs.
Journal: The Journal of antimicrobial chemotherapy
Published: June 27, 2024
Clearance of archived integrase strand transfer inhibitors resistance mutations in people with virologically suppressed HIV infection.
Journal: JAC-antimicrobial resistance
Published: June 25, 2024
Ultra-rapid selection of the N74D capsid inhibitor resistance mutation after 3 weeks on lenacapavir.
Ultra-rapid selection of the N74D capsid inhibitor resistance mutation after 3 weeks on lenacapavir.
Journal: The Journal of antimicrobial chemotherapy
Published: April 17, 2024
The RT M184V resistance mutation clearance in the reservoir is mainly related to CD4 nadir and viral load zenith independently of therapeutic regimen type.
Journal: The Journal of antimicrobial chemotherapy
Published: February 12, 2024
Is vaccine response to SARS-CoV-2 preserved after switching to anti-CD20 therapies in patients with multiple sclerosis or related disorders?
Journal: Journal of neurology, neurosurgery, and psychiatry
Published: May 03, 2023
Doravirine plus lamivudine two-drug regimen as maintenance antiretroviral therapy in people living with HIV: a French observational study.
Journal: The Journal of antimicrobial chemotherapy
Published: March 27, 2023
Intermittent Bictegravir/Emtricitabine/Tenofovir Alafenamide Treatment Maintains High Level of Viral Suppression in Virally Suppressed People Living with HIV.
Journal: Journal of personalized medicine
Published: February 09, 2023
Intermittent doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF) maintains a high level of viral suppression in virologically suppressed people living with HIV.
Journal: Infectious diseases now
Published: January 17, 2023
Last Updated: 09/26/2026